Literature DB >> 26278320

Disparities in care for patients with curable hepatocellular carcinoma.

Blaire Burman1, W Scott Helton2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26278320      PMCID： PMC4557646          DOI： 10.1111/hpb.12477

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN： 1365-182X            Impact factor:   3.647


× No keyword cloud information.
  12 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

Review 2.  Treatment strategies for hepatocellular carcinoma in cirrhosis.

Authors:  W Scott Helton; Adrian Di Bisceglie; Ravi Chari; Myron Schwartz; Jordi Bruix
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

Review 3.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

4.  Patients' preferences and trade-offs for the treatment of early stage hepatocellular carcinoma.

Authors:  Michele Molinari; Sarah De Coutere; Murray Krahn; Scott Helton; David R Urbach
Journal:  J Surg Res       Date:  2014-02-15       Impact factor: 2.192

5.  Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.

Authors:  Jean-Nicolas Vauthey; Elijah Dixon; Eddie K Abdalla; W Scott Helton; Timothy M Pawlik; Bachir Taouli; Antoine Brouquet; Reid B Adams
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

Review 6.  Surgical treatment of hepatocellular carcinoma: expert consensus statement.

Authors:  William Jarnagin; William C Chapman; Steven Curley; Michael D'Angelica; Charles Rosen; Elijah Dixon; David Nagorney
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

7.  Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.

Authors:  Jessica A Davila; Robert O Morgan; Peter A Richardson; Xianglin L Du; Katherine A McGlynn; Hashem B El-Serag
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

8.  Racial, social, and clinical determinants of hepatocellular carcinoma surveillance.

Authors:  Amit G Singal; Xilong Li; Jasmin Tiro; Pragathi Kandunoori; Beverley Adams-Huet; Mahendra S Nehra; Adam Yopp
Journal:  Am J Med       Date:  2014-08-10       Impact factor: 4.965

Review 9.  Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States.

Authors:  D Tan; A Yopp; M S Beg; P Gopal; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2013-08-19       Impact factor: 8.171

10.  Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.

Authors:  Amit G Singal; Anjana Pillai; Jasmin Tiro
Journal:  PLoS Med       Date:  2014-04-01       Impact factor: 11.069
View more
  2 in total

1.  Liver Transplantation Versus Liver Resection for Stage I and II Hepatocellular Carcinoma: Results of an Instrumental Variable Analysis.

Authors:  Wei Li; Haitao Xiao; Hong Wu; Xuewen Xu; Yange Zhang
Journal:  Front Oncol       Date:  2021-05-26       Impact factor: 6.244

2.  Management and survival for patients with stage-I hepatocellular carcinoma: An observational study based on SEER database.

Authors:  Zhaoping Wu; Weili Chen; Ting Ouyang; Hechun Liu; Lingling Cao
Journal:  Medicine (Baltimore)       Date:  2020-10-09       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.